ORENCIA (Bristol-Myers Squibb Australia Pty Ltd)
Product name
ORENCIA
Date registered
Evaluation commenced
Decision date
Approval time
208 working days (255)
Active ingredients
abatacept (rch)
Registration type
EOI
Indication
ORENCIA is now also indicated for the treatment of active psoriatic arthritis (PsA) in adults when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Orencia can be used with or without non-biologic DMARDs.